US FDA lifts generic office to 'super' status
This article was originally published in Scrip
Executive Summary
The US FDA has elevated yet another program office to the status of "super," meaning it consists of multiple smaller subordinate programs within its structure, with the Office of Generic Drugs (OGD) the latest to get bumped up to the new ranking.